Germany's Cannabis Appetite Is Rewriting Global Export Maps

Photo by Léster Lau via Pexels.

Walk into a licensed cannabis pharmacy in Berlin or Munich today and there's a decent chance the flower on the shelf traveled from a greenhouse outside Toronto, got reprocessed at a GMP facility in Porto, and only then crossed into Germany. That supply chain, unusual as it sounds, is now the default rather than the exception. Germany's Federal Institute for Drugs and Medical Devices, known as BfArM, logged more than 200,094 kilograms of medical cannabis imports for 2025 -- a 176% jump over 2024's already-growing total. Pharmacy sell-out sales crossed €1 billion for the first time in the same period, a threshold that turns what used to be a niche medical market into something closer to a mainstream pharmaceutical category.

What makes this lopsided is scale. Germany has 84 million people, easily the largest population of any European country with a functioning medical cannabis framework, yet it has just three domestic producers licensed to grow the plant. Almost everything consumed gets imported. That gap between demand and domestic production capacity has turned Germany into the single most important destination market for cannabis exporters worldwide, and it's pulling capital with it -- nearly €200 million in acquisitions of European cannabis assets since September 2025 alone, much of it Canadian money buying direct access to German shelves. But there's a real complication sitting in the Bundestag's spring calendar: a pending law that would effectively end remote prescribing, the mechanism that's fed a huge share of this growth. If it passes as drafted, the telemedicine pipeline that built this billion-euro market could narrow fast.

The Numbers Behind Germany's Import Boom

Germany's medical cannabis imports nearly tripled year-over-year, rising from about 72,706 kg in 2024 to 201,094 kg in 2025.

The BfArM numbers tell a growth story that's steep even by cannabis industry standards, where triple-digit percentage swings aren't unusual. Full-year 2025 imports hit 201,094 kg, up from 72,706 kg in 2024 -- essentially tripling in a single year. The momentum hasn't slowed heading into 2026 either: Q1 2026 alone brought in 50,539 kg. That figure is down about 15% from the prior quarter, which is worth noting since quarterly cannabis import data tends to be lumpy depending on shipment timing, but it's still up 34% year-over-year, which is the more meaningful comparison for a market that's still expanding rather than plateauing.

Look at the trailing four quarters and the total tops 218 tonnes, and BfArM keeps revising earlier quarters upward as more complete reporting comes in -- Q4 2025 alone got bumped from an initial 56.625 tonnes to 60.772 tonnes. That kind of upward revision pattern suggests the agency's real-time reporting is consistently underestimating actual flow, which means the true growth curve is probably even steeper than the headline numbers show.

The pharmacy sales figure is arguably the more important data point for anyone trying to understand where this market is headed, because import volume alone doesn't tell you whether product is actually reaching patients or sitting in warehouses. Crossing €1 billion in pharmacy sell-out sales for the first time in 2025 signals a retail and telemedicine infrastructure that's matured well past the early-access phase Germany was in just a few years ago. No other European country comes close to this import volume or this level of pharmacy-channel revenue, which is exactly why Germany has become the market every international producer is building strategy around.

Who's Filling the Order: Canada, Portugal, Denmark

Photo by u_nnjglrk13q via Pixabay.

Canada supplied more German medical cannabis than any other country in Q1 2026, shipping 26,753 kg -- 53% of everything Germany imported that quarter. Portugal came in second at 10,342 kg, and Denmark rounded out the top three at 3,338 kg. Those three countries alone account for the overwhelming majority of German supply, but the way Canadian product actually gets to Germany is more layered than a simple export contract.

A growing share of Canadian-grown cannabis doesn't ship directly to Germany. Instead it routes through EU-GMP-certified processors in Portugal, the Czech Republic, Malta, and Switzerland first. Industry people have started calling this GMP washing, informally and a bit cynically, but the mechanics are straightforward: EU pharmaceutical import rules require product to meet Good Manufacturing Practice standards certified within the bloc, and building an EU-GMP facility from scratch is expensive and slow. Routing raw Canadian flower through an already-certified European processor for final packaging, testing, and labeling lets growers in Ontario or British Columbia meet EU standards without ever building EU infrastructure themselves.

Portugal has been the biggest beneficiary of this pattern. Its climate makes it well-suited to outdoor and greenhouse cultivation, and its regulatory environment issued EU-GMP certifications early enough that it became the default processing stop for North American growers looking to reach Germany. That's changed what Portugal actually is in this supply chain -- it's no longer just a cultivation origin competing on its own grown flower, it's a logistics and processing hub that adds value to product grown somewhere else entirely. Denmark plays a similar, smaller-scale role, with its own greenhouse operators and processing capacity increasingly oriented toward the German pharmacy market rather than domestic Danish demand.

Germany's Thin Domestic Supply Chain

Photo by JRByron via Pixabay.

Germany's cultivation capacity is strikingly thin for a market this size. Just three companies hold licenses to grow medical cannabis domestically, serving a country of 84 million people. Two of those three trace their corporate roots to Canada -- one tied to Tilray/Aphria's German operations, the other to Aurora -- which means even Germany's homegrown supply is substantially foreign-owned in practice, if not in geography.

The contrast with Canada is stark. Canada has nearly 1,000 licensed cannabis producers for a population of roughly 40 million people, meaning it has roughly 25 producers for every one Germany has, adjusted for population that gap widens even further. Canada built that capacity over almost a decade of federal legalization policy aimed explicitly at creating a domestic industry with export ambitions. Germany's medical cannabis framework, by contrast, was built around patient access and import approval, not domestic cultivation buildout, and licensing new German growers has moved slowly.

The result shows up clearly in trade data going the other direction. Germany's own medical cannabis exports actually fell 21% in 2025, down to 5.9 tonnes -- a rounding error next to the 200-plus tonnes coming in. Germany isn't positioning itself as a cannabis supplier to neighboring markets; it's a demand sink, full stop. That structural imbalance, thin domestic cultivation against enormous and growing patient demand, is the single biggest reason foreign exporters have as much pricing and negotiating leverage in Germany as they do. There's effectively no domestic industry large enough to compete with imported product on price or volume, so the market clears almost entirely on terms set by exporters and the processors who service them.

Canada's Export Pivot and the Money Chasing It

Photo by Bia Limova via Pexels.

Canadian licensed producers didn't stumble into the German export opportunity -- they built toward it deliberately, in part because of how Canada's own tax structure works. Canada charges a $1-per-gram excise tax on cannabis sold domestically, a levy that doesn't apply to product exported for sale abroad. That tax gap alone makes overseas margins meaningfully more attractive than domestic Canadian sales, especially in a home market where retail prices have been ground down by years of oversupply and provincial competition.

Ottawa has taken notice of where the growth actually is. On May 4, 2026, Canadian cannabis industry representatives sat down with the Parliamentary Secretary to the Minister of International Trade along with the Trade Commissioner Service specifically to talk through export opportunities -- a sign that what started as company-level strategy is now getting attention as a trade-policy conversation at the federal level.

The clearest evidence of how seriously Canadian producers are taking the German opportunity is the acquisition activity. Between September 2025 and February 2026, three Canadian-led deals put close to €200 million into European cannabis assets. The largest by far is Organigram's acquisition of Sanity Group, a German cannabis company, valued at up to €250 million depending on earn-out terms. Deals like this aren't about securing a supply contract that could be renegotiated or canceled -- they're about owning the German distribution relationship outright, cutting out the uncertainty of depending on a third-party importer or wholesaler to move product through pharmacies. That's a meaningful shift in posture: Canadian firms have gone from being suppliers to a foreign market to being owners of pieces of that market's actual retail and distribution machinery.

The Regulatory Cloud: A Telemedicine Crackdown Looms

Photo by Tima Miroshnichenko via Pexels.

All of this growth is sitting on top of a regulatory question that hasn't been resolved yet, and the answer could reshape the entire trade relationship. Germany's Federal Cabinet approved a MedCanG amendment bill on October 8, 2025 aimed squarely at remote prescribing -- the telemedicine model that's driven a large share of the pharmacy sales growth by letting patients get a cannabis prescription through an online consultation rather than an in-person doctor visit.

The bill as drafted would ban mail-order cannabis sales outright and require an in-person visit before a patient can receive a first prescription. Follow-up prescriptions would need an in-person visit at least once within the preceding four quarters, closing off the fully-remote model that some telemedicine platforms and pharmacy-delivery services have built their entire business around. Second and third readings in the Bundestag are planned for spring 2026, and if the bill clears those readings without major amendment, earliest implementation would likely land in spring or summer 2026.

Industry analysts are treating this as a live risk rather than a formality. Alfredo Pascual, who covers the German cannabis market closely, has flagged clear risk that regulators are specifically targeting the high-volume telemedicine and pharmacy-delivery models that have been the fastest-growing part of the market -- which is a notable distinction, because it means the crackdown isn't aimed at medical cannabis broadly but at the exact channel responsible for pushing sales past €1 billion.

If that channel narrows, the effect wouldn't stay contained to German telemedicine companies. A sharp drop in German patient volume would ripple straight back through the supply chain to Canadian growers who've scaled operations around German export demand, and to the Portuguese and Danish processors whose entire business model now depends on German pharmacy sell-through. The law hasn't passed yet, but everyone with exposure to this trade is already pricing in the possibility that it will.

It's worth stepping back and naming what's actually happened here: Germany's import boom has functioned as an accidental industrial policy for Canadian and Portuguese cannabis exporters. No trade agreement engineered this outcome. A domestic access framework that never built out matching cultivation capacity did, and the companies smart enough to notice the gap early -- Canadian growers with excess capacity and no domestic excise-tax penalty for exporting, Portuguese processors with early EU-GMP certification -- have captured the value that gap created.

The prescription law is the variable that matters most right now, more than any single supply contract or acquisition. It could cut off the telemedicine funnel that pushed pharmacy sales past €1 billion in the first place, and that's precisely why growers in Ontario and processors in Lisbon are watching the Bundestag's spring reading schedule as closely as they're watching their own harvest cycles. A market this dependent on one prescribing channel is a market with real concentration risk, and the companies with the most exposure know it.

Expect the acquisition pace to continue rather than cool off. When the regulatory ground under an export contract is this uncertain, owning a piece of German distribution outright looks a lot safer than betting that today's rules still apply next year. Organigram's move on Sanity Group won't be the last deal of its kind -- if anything, a looming crackdown gives foreign producers more reason to lock in ownership now, before the terms of access potentially change under them.